184 related articles for article (PubMed ID: 6097267)
1. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
Bünning P
Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Schölkens BA; Becker RH; Kaiser J
Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
[TBL] [Abstract][Full Text] [Related]
4. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
Unger T; Fleck T; Ganten D; Lang RE; Rettig F
Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
[TBL] [Abstract][Full Text] [Related]
5. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
Metzger H; Maier R; Sitter C; Stern HO
Arzneimittelforschung; 1984; 34(10B):1402-6. PubMed ID: 6097265
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Teetz V; Geiger R; Henning R; Urbach H
Arzneimittelforschung; 1984; 34(10B):1399-401. PubMed ID: 6097264
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
Witte PU; Metzger H; Eckert HG; Irmisch R
Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
[TBL] [Abstract][Full Text] [Related]
8. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
Felder K; Witte PU
Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
[TBL] [Abstract][Full Text] [Related]
10. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
11. General pharmacology of ramipril.
Omosu M; Komine I; Becker RH; Schölkens BA
Arzneimittelforschung; 1988 Sep; 38(9):1309-17. PubMed ID: 2975947
[TBL] [Abstract][Full Text] [Related]
12. Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine.
Hajdú P; Schmidt D; Bomm M; Hack L; Keller A
Arzneimittelforschung; 1984; 34(10B):1431-5. PubMed ID: 6097270
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitor.
Sybertz EJ; Baum T; Ahn HS; Nelson S; Eynon E; Desiderio DM; Pula K; Becker F; Sabin C; Moran R; Vander Vliet G; Kastner B; Smith E
J Cardiovasc Pharmacol; 1983; 5(4):643-54. PubMed ID: 6193364
[TBL] [Abstract][Full Text] [Related]
14. Acute, subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril.
Donaubauer HH; Mayer D
Arzneimittelforschung; 1988 Jan; 38(1):14-20. PubMed ID: 2966628
[TBL] [Abstract][Full Text] [Related]
15. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.
Caspritz G; Alpermann HG; Schleyerbach R
Arzneimittelforschung; 1986 Nov; 36(11):1605-8. PubMed ID: 3028436
[TBL] [Abstract][Full Text] [Related]
16. A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite.
Eckert HG; Münscher G; Oekonomopulos R; Strecker H; Urbach H; Wissmann H
Arzneimittelforschung; 1985; 35(8):1251-6. PubMed ID: 3000393
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Met5-enkephalin-Arg6-Phe7 degradation by inhibitors of dipeptidyl carboxypeptidase.
Mellstrom B; Iadarola MJ; Yang HY; Costa E
J Pharmacol Exp Ther; 1986 Oct; 239(1):174-8. PubMed ID: 2945003
[TBL] [Abstract][Full Text] [Related]
18. Effect of peptidase inhibitors on [Met5]enkephalin-Arg6-Phe7 and [Met5]enkephalin-Arg6-Gly7-Leu8-induced antinociception.
Mellstrom B; Iadarola MJ; Costa E
Eur J Pharmacol; 1987 Jan; 133(2):185-90. PubMed ID: 2949992
[TBL] [Abstract][Full Text] [Related]
19. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.
van Gilst WH; de Graeff PA; Wesseling H; de Langen CD
J Cardiovasc Pharmacol; 1986; 8(4):722-8. PubMed ID: 2427810
[TBL] [Abstract][Full Text] [Related]
20. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
